Analyzing Turnstone Biologics (NASDAQ:TSBX) & Krystal Biotech (NASDAQ:KRYS)

Turnstone Biologics (NASDAQ:TSBX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Valuation and Earnings

This table compares Turnstone Biologics and Krystal Biotech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turnstone Biologics	$19.31 million	0.75	-$55.20 million	($10.14)	-0.06
Krystal Biotech	$166.23 million	31.64	$10.93 million	$1.87	98.49

Krystal Biotech has higher revenue and earnings than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Turnstone Biologics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Turnstone Biologics and Krystal Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Turnstone Biologics	N/A	-85.18%	-72.25%
Krystal Biotech	63.73%	1.99%	1.87%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Turnstone Biologics and Krystal Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turnstone Biologics	0	0	2	0	3.00
Krystal Biotech	0	1	7	1	3.00

Turnstone Biologics presently has a consensus price target of $6.88, indicating a potential upside of 991.27%. Krystal Biotech has a consensus price target of $196.75, indicating a potential upside of 6.83%. Given Turnstone Biologics’ higher probable upside, research analysts plainly believe Turnstone Biologics is more favorable than Krystal Biotech.

Summary

Krystal Biotech beats Turnstone Biologics on 11 of the 14 factors compared between the two stocks.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.